Toward optimal moxifloxacin dosing in tuberculous meningitis: A translational physiologically based pharmacokinetic modeling approach

These results suggest that higher doses might be needed to ensure PK target attainment in TBM, regardless of whether moxifloxacin is combined with rifampicin. The safety of regimens exceeding 800 mg must be rigorously established in clinical trials.